Necrotic core formation in advanced atherosclerotic lesion, which is a collection of dead and necrotic macrophages surrounded by inflammatory cells, contributes to inflammation, plaque disruption, and thrombosis and leads to vulnerable plaque formation. Especially, defective phagocytic clearance (efferocytosis) of dying cells is critically linked to progression of advanced atherosclerotic lesions. Efferocytosis can involve many molecules including find me and eat me signaling molecules and bridging molecules including opsonins, but its comprehesive regulatory mechanism in advanced lesion of atherosclerosis remains unclear. Our data show that addition of apoptotic cells (ACs) activates ERK5 kinase in macrophages and accelerates efferocytosis via secretion of opsonins, whereas these responses are inhibited in macrophages from ERK5 knock-out (ERK5- MKO) mice. Indeed, ERK5-MKO mice showed increased necrotic core and atherosclerosis formation. Since macrophage angiotensin II type 1 receptor (AT1) was involved in efferocytosis, the major hypothesis is that macrophage ERK5 kinase activation by ACs is a key event in efferocytosis in the advanced lesion of atheroslcerosis and p90RSK activation under angiotensin II inhibits efferocytosis by inhibiting ERK5 transcriptional activity. We will experimentally determine the mechanisms by which macrophage ERK5 regulates efferocytosis as a sensor of ACs in Aim 1 and Aim2.
In Aim 3, we will use genetic mouse models to determine the role of macrophage ERK in necrotic core formation in atherosclerotic lesions.
In Aim 4, we will investigate the possible role of macrophage p90RSK in regulating ERK5 activity in efferocytosis and atherosclerosis formation. The significance of our study is in providing a mechanistic understanding of the clinically well-described cardiac risk of acute atherothrombotic vascular disease in advanced atherosclerotic lesions. Understanding the role and molecular mechanisms of ERK5-mediated efferocytosis as well as inhibition of necrotic core and atherosclerosis formation should provide insights into the cause of acute atherothrombotic vascular diseases in advanced lesion and possibly reveal a novel therapeutic targets.
The key role of efferocytosis in atherosclerosis and the stability of vulnerable plaques have become increasingly evident. We anticipate that specific macrophage ERK5 downregulation and subsequent reduced expression of ERK5 targeted molecules including efferocytosis-related genes make macrophages atheroprone and form a vulnerable plaque accumulating apoptotic debris and necrotic core. Mechanistically, we have found that p90RSK regulates the ERK5 effects on the efferocytosis process as a negative regulator. Therefore, the activation of ERK5 and inhibition of p90RSK activity could emerge as novel therapeutic targets to tackle the highly relevant problem of managing vulnerable plaques from rupture.
|Heo, Kyung-Sun; Berk, Bradford C; Abe, Jun-Ichi (2016) Disturbed Flow-Induced Endothelial Proatherogenic Signaling Via Regulating Post-Translational Modifications and Epigenetic Events. Antioxid Redox Signal 25:435-50|
|Chang, Eugene; Abe, Jun-Ichi (2016) Kinase-SUMO networks in diabetes-mediated cardiovascular disease. Metabolism 65:623-33|
|Abe, Jun-Ichi (2016) Multiple Functions of Protein Inhibitor of Activated STAT1 in Regulating Endothelial Cell Proliferation and Inflammation. Arterioscler Thromb Vasc Biol 36:1717-9|
|Abe, Jun-Ichi; Morrell, Craig (2016) Pyroptosis as a Regulated Form of Necrosis: PI+/Annexin V-/High Caspase 1/Low Caspase 9 Activity in Cells = Pyroptosis? Circ Res 118:1457-60|
|Abe, Jun-Ichi; Martin, James F; Yeh, Edward T H (2016) The Future of Onco-Cardiology: We Are Not Just ""Side Effect Hunters"". Circ Res 119:896-9|
|Heo, Kyung-Sun; Le, Nhat-Tu; Cushman, Hannah J et al. (2015) Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest 125:1299-310|
|Heo, Kyung-Sun; Cushman, Hannah J; Akaike, Masashi et al. (2014) ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis. Circulation 130:180-91|